Characteristic | VEM1-IPI (n = 46) |
---|---|
Age, years | |
Mean (SD) | 55.0 (14.20) |
Gender, n (%) | |
Male | 37 (80.4) |
ECOG performance status, n (%) | |
0 | 35 (76.1) |
1 | 11 (23.9) |
Disease stage at study entry, n (%) | |
III | 8 (17.4) |
IV | 38 (82.6) |
M-stage at study entry, n (%) | |
M0 | 6 (13.0) |
M1a | 8 (17.4) |
M1b | 8 (17.4) |
M1c | 24 (52.2) |
Number of disease sites, n (%) | |
1 | 2 (4.3) |
2 | 8 (17.4) |
3 | 7 (15.2) |
4 | 4 (8.7) |
≥ 5 | 25 (54.3) |
ECOG Eastern Cooperative Oncology Group, IPI ipilimumab, SD standard deviation, VEM vemurafenib